Clinical Trials Browser

Withdrawn × INDUSTRY × Lymphoma, T-Cell, Peripheral × Clear all

NCT03999658 2023-05-01

A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Cholangiocarcinoma, Lymphoma, Extranodal NK-T-Cell

NCT04021082 2023-02-21

CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)

Phase 2/3 Withdrawn

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, T-Cell, Lymphoma, T-Cell, Peripheral

NCT05239910 2022-10-17

Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL

Phase 2 Withdrawn

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT03553914 2020-10-19

PLM60 for Peripheral T Cell Lymphoma (PTCL)

Phase 1/2 Withdrawn

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT01355783 2013-11-18

A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma

Phase 3 Withdrawn

Lymphoid

Lymphoma, T-Cell, Peripheral